
Utz Launches Limited Edition Lemonade Potato Chips
HANOVER, Pa.--(BUSINESS WIRE)-- Utz ®, a leading U.S. salty snack brand, has teamed up with Alex's Lemonade Stand Foundation, the largest independent childhood cancer charity in the U.S., to introduce its latest innovation: lemonade-flavored potato chips. The new Utz Lemonade Potato Chips combine the tangy sweetness of lemonade with the classic salty crunch of Utz potato chips, delivering a bold, unique flavor experience.
'Just in time for summer, Utz Lemonade Potato Chips bring together the nostalgic sweet and tart taste of classic lemonade with the satisfying crunch of another seasonal favorite – potato chips. The new chips are summer in a bite,' said Stacey Schultz, senior vice president of marketing at Utz Quality Foods, LLC, a subsidiary of Utz Brands, Inc. 'Beyond the incredible taste, we are also thrilled to partner with and support Alex's Lemonade Stand Foundation's incredible work in the fight against childhood cancer.'
This limited edition flavor is available in a 7.75-oz. bag through August, while supplies last, online at utzsnacks.com and in leading retailers nationwide. Utz will donate a portion of each bag sold, up to $25,000, to Alex's Lemonade Stand Foundation, funding critical research and support for children battling cancer.
'At Alex's Lemonade Stand Foundation, we believe that every effort—big or small—helps move us closer to cures for all kids,' said Liz Scott, Alex's mom and co-executive director at Alex's Lemonade Stand Foundation. 'This partnership with Utz is a fun and meaningful way to bring awareness to our mission, and we're looking forward to seeing snackers nationwide join the fight against childhood cancer.'
Consumers can learn more about Alex's Lemonade Stand Foundation and support their fight against childhood cancer by visiting AlexsLemonade.org. To learn more about Utz and its new flavors, connect with Utz on Facebook, Instagram and TikTok, and find Alex's Lemonade Stand Foundation on Facebook, Instagram and TikTok.
#UTZLEMONADEPOTATOCHIPS
About Utz Brands, Inc.
Utz Brands, Inc. (NYSE: UTZ) manufactures a diverse portfolio of savory snacks through popular brands, including Utz ®, On The Border ® Chips & Dips, Zapp's ®, and Boulder Canyon ®, among others.
After a century with a strong family heritage, Utz continues to have a passion for exciting and delighting consumers with delicious snack foods made from top-quality ingredients. Utz's products are distributed nationally through grocery, mass merchandisers, club, convenience, drug, and other channels. Based in Hanover, Pennsylvania, Utz has multiple manufacturing facilities across the U.S. to serve its growing customer base. For more information, please visit www.utzsnacks.com or call 1‐800‐FOR‐SNAX.
About Alex's Lemonade Stand Foundation
Alex's Lemonade Stand Foundation (ALSF) emerged from the front yard lemonade stand of 4-year-old Alexandra 'Alex' Scott, who was fighting cancer and wanted to raise money to find cures for all children with cancer. By the time Alex passed away at the age of 8, she had raised $1 million. Since then, the Foundation bearing her name has evolved into a worldwide fundraising movement and one of the largest independent childhood cancer charities in the U.S. ALSF is a leader in funding pediatric research projects across the globe and providing programs to families affected by childhood cancer. For more information, visit AlexsLemonade.org.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
20 minutes ago
- Yahoo
United Healthcare: Earnings, A $200 Billion Overreaction
One of the most dramatic reactions from the Q1 2025 earnings season came from United Healthcare (NYSE:UNH), which shed over $200 billion in market cap and cratered 23% intra-day post-earnings along with continued decline upon the resignation of its CEO and a potential DOJ inquiry. At first glance, that kind of move suggests something catastrophic although the actual results paint a very different picture. Warning! GuruFocus has detected 4 Warning Sign with UNH. The selloff was driven by a 2% increase in Medicare Advantage costs and higher utilization trends (greater related medical expenses), which led to a reduction in 2025 earnings guidance from $29 to $26 per share initially and later with guidance lifted. That's collectively a $3 hit to EPS which is material from initial guidance, but not earth-shattering especially considering UNH is stil projected to have 20.65 billion in 2024 full year net income based on revisions of major investment banks aggregated by Refinitiv along with 25-30 billion for FY26. That level of profit implies a P/E of roughly 12 and a forward P/E of less than 10 (representing a forward cash flow yield of 10%, a truly absurd financial metric for a company of this size), which is deeply discounted for a business of this scale, profitability, and consistency. The increase in utilization is also expected within the earnings call to normalize to historical averages in the near future and this isn't the first time a Medicare Advantage utilization has caused the share price to decline. In June 2023 a similar utilization increase was seen and the effects were short lived, negligible to profitability and the share price quickly was achieving new highs just a six weeks later. Given how the insurance operation works, premiums can also be raised to offset additional care expenses encountered to maintain similar margins and levels of profitability. The CEO also stepped down due to stated personal reasons, while for investors having a CEO step down is typically seen as something negative, the successor for the position is the long term prior CEO Steven J Hemsley, an executive that oversaw exceptional increases in financial operations, efficiency, and stewardship of the company through industry opportunities. While the stock declined rather significantly upon his appointment, this would seem to be dramatic given the prior CEO executed incredible shareholder returns and growth of operations. The last contributor to major negative sentiment is the "announcement/accusation" by journalists a DOJ probe into medicare advantage billing escalating from civil to criminal (uncorroborated by the DOJ or any legal agency), the company explicitly denied any knowledge or informational requests related to such a probe or its supposed existence and given a prior legal ruling in the civil case that there was no apparent incorrect coding for billing, the legitimacy of this seems to be in question. While if the probe is found to be legitimate in the future, as incredible as it sounds, the company would also likely not have any difficulty financing a fine/outlay of significant size. UNH generates profits from a few large business segments albeit diversified due to the massive scale, the insurance operation in which premiums are received and invested/used to pay out claims respectfully and represents the largest health insurer in the US. The other major component of business operations is Optum, which consists of its pharmacy benefit manager operations, Optum Health which directs healthcare directly, and Optum Insights which provides data analytics and consulting. The hit to guidance was within the legacy insurance segment, which remains wildly profitable although the real driver of earnings growth (a greater than 50% share of net income) is seen within Optum which would seem to be unaffected. UNH's capital allocation strategy has historically been a masterclass in shareholder returns. The company has averaged 2-4 billion in quarterly stock buybacks, while simultaneously paying out close to $8 billion in annual dividends all without compromising operations or balance sheet strength. The most recent buyback spike in Q4 2024 was nearly $5 billion, the largest in the past three years. Based on the outlandish profitability of UNH and the businesses clear willingness and ability to reward shareholders, once you throw in the fact that there is a significant discount being placed on the business by the market, it becomes clear this is a sizable overreaction and not reflective of the operations or strength of the company. *historically repurchases accelerate for UNH under market declines This level of profitability and shareholder alignment is rare, and it's even more compelling now that the market has mispriced the stock on short-term guidance noise. The biggest opportunities in investing often come when price temporarily detaches from financial reality and that's exactly what this looks like. With the regime of a current market built on fear and facing macroeconomic struggles, health insurance is generally considered a defensive, non-cyclical industry because demand for healthcare remains relatively stable regardless of economic conditions. People don't stop needing medical care during a recession and if anything, economic stress can drive higher Medicaid enrollment or subsidized marketplace coverage. For insurers like UNH, revenue is largely tied to premiums and government reimbursements, which are contractual or regulated and don't fluctuate with consumer sentiment or discretionary spending trends. Even during downturns, enrollment can remain stable or even grow as individuals shift from employer-sponsored plans to government-backed options. Unlike cyclical sectors like consumer discretionary or industrials, healthcare spending is inelastic and people prioritize it no matter what. Moreover, Medicare Advantage and Medicaid, which are a large part of UNH's book, are government-funded and relatively insulated from short-term economic cycles. As for the broader industry landscape, there are no meaningful moves underway to undercut or dismantle the private health insurance model. The regulatory outlook remains stable, and there are no current legislative pressures that would structurally alter the business model of companies like UNH. Importantly, this volatility in premiums is limited to the UnitedHealthcare segment. Optum UNH's faster-growing, higher margin division which continues to deliver strong performance across health services, pharmacy benefits, and data analytics. Together, this structure gives UNH a diversified revenue model that can weather temporary shocks in one segment without compromising overall earnings power and represents a significantly undervalued equity at current market prices. * TipRanks. (n.d.). UnitedHealth (NYSE:UNH) stock buybacks. Retrieved May 3, 2025, from This article first appeared on GuruFocus.
Yahoo
34 minutes ago
- Yahoo
Mattermost Names James Mullins as Vice President of Sales for EMEA and APAC
Proven sales leader brings over 30 years of technology sales experience to drive Mattermost's global growth strategy James Mullins PALO ALTO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Mattermost, Inc., the trusted leader in secure, real-time collaboration and workflow solutions for defense, intelligence, security, and critical infrastructure, today announced the appointment of James Mullins as Vice President of Sales for Europe, Middle East, Africa (EMEA) and Asia Pacific (APAC) regions. Mullins brings more than three decades of experience in technology sales leadership, with a proven track record of driving global sales growth and developing strategic market initiatives. "James' extensive experience in scaling sales organizations and his deep understanding of international markets make him the ideal leader to expand our presence across EMEA and APAC," said Dave Reardon, CRO at Mattermost. "His expertise in enterprise sales and proven ability to drive growth will be invaluable as we continue to accelerate our global expansion and help more organizations enhance their secure collaboration capabilities." Prior to joining Mattermost, Mullins led the business development function at Ripjar and KYC360, where he successfully implemented sales strategies that drove company growth. Throughout his career, he has held senior sales leadership positions where he has built and led high-performing global sales teams from startup to scale-up phases. "I'm thrilled to join Mattermost at such an exciting time in the company's journey," said Mullins. "The demand for secure, flexible collaboration solutions continues to grow exponentially, particularly among technical teams and organizations with complex security and compliance requirements. I look forward to working with the Mattermost team to expand our global footprint and deliver exceptional value to customers across EMEA and APAC." Mullins has successfully sold into multiple vertical markets including Financial Services, Insurance, Telecommunications, Government, and Oil & Gas. His expertise in driving both sales and market development strategies has consistently delivered strong business results throughout his 30-year career in technology sales. In his new role, Mullins will focus on accelerating Mattermost's growth strategy across EMEA and APAC regions, expanding the company's enterprise customer base, and strengthening strategic partnerships to enhance market presence. About Mattermost Mattermost is the Intelligent Mission Environment that delivers secure chat operations and collaborative workflows for mission-critical work in defense, government, and critical infrastructure. Trusted by the U.S. Department of Defense and Fortune 500s, our open core platform powers focused, adaptable, secure, resilient operations across the most demanding environments. The platform supports Mission Operations, DevSecOps, and Cyber Defense with secure messaging, file sharing, audio calling, screen sharing, workflow automation, and AI assistance—available in self-hosted and on-demand deployments from strategic partners. Built on an open source platform shaped by 4,000+ contributors, Mattermost is co-developed with the world's top security experts to meet the most demanding operational needs. Learn more at Attachment James Mullins CONTACT: Mattermost press@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Jim Cramer Recommends Royal Caribbean Cruises Over Viking Holding (VIK)
We recently published a list of . In this article, we are going to take a look at where Viking Holdings Ltd (NYSE:VIK) stands against other stocks that Jim Cramer discusses. A caller asked for Cramer's thoughts on Viking Holdings Ltd (NYSE:VIK), and he replied: 'Okay, I like Viking, but I thought they were tepid when they came on, and therefore I'm going to send you to Royal. I think RCL is now the gold standard, and that's the one I want to own.' Viking (NYSE:VIK) provides transport services for travelers and offers tourism experiences that include guided tours and other activities for its guests. Moreover, on March 14, Cramer was bullish on the company as he said: 'Regular viewers know I am a big fan of the cruise lines… Viking's a unique player with an impressive focus on rich American baby boomers. We watched with glee as Viking stock glided higher and higher and higher throughout last year and even the first few weeks of 2025, eventually it peaked at 53 bucks and change in early February just before the market-wide sell-off. Since then, the stock's fallen back to $40, down roughly 25% from its highs just over a month ago… The cruise lines are different from other travel plays. They represent incredible value versus traditional vacation alternatives…For Viking in particular, we have a fresher company-specific catalyst. On Tuesday morning, the company reported an excellent quarter with in-line revenue and impressive 9-cent earnings beat off a 36-cent basis… Overall, VIK ranks 5th on our list of stocks that Jim Cramer discusses. While we acknowledge the potential of VIK as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires. Disclosure: None. This article is originally published at Insider Monkey.